Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin

BACKGROUND: For many indications, BoNT/A is repetitively injected with the risk of developing neutralizing antibodies (NABs). Therefore, it is important to analyze whether there is a difference in antigenicity between the different licensed BoNT/A preparations. METHODS: In this cross-sectional study...

Descripción completa

Detalles Bibliográficos
Autores principales: Hefter, Harald, Rosenthal, Dietmar, Jansen, Alexander, Brauns, Raphaela, Ürer, Beyza, Bigalke, Hans, Hartung, Hans-Peter, Meuth, Sven G., Lee, John-Ih, Albrecht, Philipp, Samadzadeh, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886600/
https://www.ncbi.nlm.nih.gov/pubmed/36195775
http://dx.doi.org/10.1007/s00415-022-11395-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886600/
https://www.ncbi.nlm.nih.gov/pubmed/36195775
http://dx.doi.org/10.1007/s00415-022-11395-2

Ejemplares similares